Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 350Polycystic Ovary Syndrome 39Endometrial Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 16Infertility 12Neoplasms 11Fallopian Tube Neoplasms 8Advanced Breast Cancer 8Triple Negative Breast Neoplasms 7Carcinoma, Intraductal, Noninfiltrating 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Recurrence 6Osteoporosis 6Carcinoma, Lobular 6Breast Diseases 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Anovulation 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

Trastuzumab 30pertuzumab 16Docetaxel 16pyrotinib 11Paclitaxel 7Carboplatin 5Capecitabine 5Ado-Trastuzumab Emtansine 4tucatinib 3trastuzumab deruxtecan 2atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-positive Breast Cancer × Letrozole × Clear all
NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

University of Kansas Medical Center

Phase 1/2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡